Damir Vrbanec

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

Sandra M. Swain, David Miles, Sung‐Bae Kim et al. · The Lancet Oncology · 2020 · 854 citations

End-of-study Results, Breast Oncology, Medicine +8

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 578 citations

5-Year Analysis, Breast Oncology, Oncology +10

Delays in diagnosis and treatment of breast cancer: a multinational analysis

Jacek Jassem, Vahit Özmen, Florin Bacanu et al. · European Journal of Public Health · 2013 · 145 citations · Full text

Single-Nucleotide Polymorphisms in Genes Encoding Toll-Like Receptor -2, -3, -4, and -9 in Case–Control Study with Breast Cancer

Godfrey E. Etokebe, Jelena Knežević, Branka Petričević et al. · Genetic Testing and Molecular Biomarkers · 2009 · 52 citations

FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study

Klaus Kaczirek, Tudor–Eliade Ciuleanu, Damir Vrbanec et al. · Clinical Colorectal Cancer · 2014 · 29 citations

Tumor Ras, Gastrointestinal Oncology, Medicine +10